JP2020511548A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511548A5 JP2020511548A5 JP2020501424A JP2020501424A JP2020511548A5 JP 2020511548 A5 JP2020511548 A5 JP 2020511548A5 JP 2020501424 A JP2020501424 A JP 2020501424A JP 2020501424 A JP2020501424 A JP 2020501424A JP 2020511548 A5 JP2020511548 A5 JP 2020511548A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- therapeutically effective
- composition according
- amount
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 24
- 231100000618 Neurotoxin Toxicity 0.000 claims 9
- 108020003835 TX1 Proteins 0.000 claims 9
- 239000002581 neurotoxin Substances 0.000 claims 9
- 108030001720 Bontoxilysin Proteins 0.000 claims 5
- 231100001103 botulinum neurotoxin Toxicity 0.000 claims 5
- 230000037303 wrinkles Effects 0.000 claims 3
- 229940094657 Botulinum Toxin Type A Drugs 0.000 claims 2
- 208000002847 Surgical Wound Diseases 0.000 claims 2
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims 2
- 200000000019 wound Diseases 0.000 claims 2
- 210000004709 Eyebrows Anatomy 0.000 claims 1
- 238000002316 cosmetic surgery Methods 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000037390 scarring Effects 0.000 claims 1
Claims (19)
- 美容処置を行う方法において使用するための、速効性神経毒素を含む組成物であって、前記方法が、治療有効量の速効性神経毒素を患者に対し、治療が望まれる部域に投与することを含む、前記組成物。
- 前記速効性神経毒素が、ボツリヌス神経毒素血清型Ｅを含む、請求項１に記載の組成物。
- 前記治療有効量が、約０．２から約２０ナノグラム（ｎｇ）の範囲の量である、請求項２に記載の組成物。
- 前記治療有効量が、約０．７から約１５ｎｇの範囲の量である、請求項３に記載の組成物。
- 前記美容処置が、眉間のしわの出現を減少させることを含む、請求項１〜４のいずれか１項記載の組成物。
- 眉間のしわの出現を減少させる方法において使用するための、眉間のしわを処置するためのボツリヌス神経毒素血清型Ｅを含む組成物であって、前記方法は、約０．７から約１５ｎｇの範囲の量のボツリヌス神経毒素血清型Ｅを眉間複合体に投与することを含む、前記組成物。
- 以前の美容処置を修正する方法において使用するための、速効性神経毒素を含む組成物であって、前記方法が、治療有効量の速効性神経毒素を患者に対し、以前に美容処置を受けた部域の近接に投与することを含む、前記組成物。
- 前記速効性神経毒素が、ボツリヌス神経毒素血清型Ｅを含む、請求項７に記載の組成物。
- 前記治療有効量が、約０．２から約２０ｎｇの範囲の量である、請求項８に記載の組成物。
- 前記治療有効量が、約０．７から約１５ｎｇの範囲の量である、請求項９に記載の組成物。
- 傷跡を最小限にする方法において使用するための、短時間作用性神経毒素を含む組成物であって、前記方法は、治療有効量の短時間作用性神経毒素を患者に対し、創傷の近接に投与することを含み、前記治療有効量は約０．２から約２０ｎｇの範囲の量である、前記組成物。
- 前記短時間作用性神経毒素がボツリヌス神経毒素血清型Ｅを含む、請求項１１に記載の組成物。
- 前記治療有効量が、約０．２から約２０ｎｇの範囲の量である、請求項１２に記載の組成物。
- 前記治療有効量が、約０．７から約１５ｎｇの範囲の量である、請求項１３に記載の組成物。
- 前記創傷が外科的切開を含む、請求項１１に記載の組成物。
- 前記外科的切開が美容外科手術の結果である、請求項１５に記載の組成物。
- 前記投与が、注射を含む、請求項１〜１６のいずれか１項に記載の組成物。
- 前記方法が、ボツリヌス毒素Ａ型を患者へ投与することをさらに含む、請求項１〜１７のいずれか１項に記載の組成物。
- 前記組成物が、さらにボツリヌス毒素Ａ型を含む、請求項１〜１８のいずれか１項に記載の組成物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023034649A JP2023076463A (ja) | 2017-03-22 | 2023-03-07 | 治療用のボツリヌス神経毒素 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762474749P | 2017-03-22 | 2017-03-22 | |
| US201762474744P | 2017-03-22 | 2017-03-22 | |
| US62/474,749 | 2017-03-22 | ||
| US62/474,744 | 2017-03-22 | ||
| US201762508215P | 2017-05-18 | 2017-05-18 | |
| US62/508,215 | 2017-05-18 | ||
| PCT/US2018/023709 WO2018175688A1 (en) | 2017-03-22 | 2018-03-22 | Botulinum neurotoxins for use in therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023034649A Division JP2023076463A (ja) | 2017-03-22 | 2023-03-07 | 治療用のボツリヌス神経毒素 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020511548A JP2020511548A (ja) | 2020-04-16 |
| JP2020511548A5 true JP2020511548A5 (ja) | 2021-05-06 |
Family
ID=63584698
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020501424A Pending JP2020511548A (ja) | 2017-03-22 | 2018-03-22 | 治療用のボツリヌス神経毒素 |
| JP2023034649A Pending JP2023076463A (ja) | 2017-03-22 | 2023-03-07 | 治療用のボツリヌス神経毒素 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023034649A Pending JP2023076463A (ja) | 2017-03-22 | 2023-03-07 | 治療用のボツリヌス神経毒素 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11260114B2 (ja) |
| EP (1) | EP3600221A4 (ja) |
| JP (2) | JP2020511548A (ja) |
| KR (1) | KR20190126894A (ja) |
| CN (1) | CN110691579A (ja) |
| AU (2) | AU2018237198B2 (ja) |
| BR (1) | BR112019019743B1 (ja) |
| CA (1) | CA3057302A1 (ja) |
| MX (2) | MX2019011196A (ja) |
| RU (2) | RU2766147C2 (ja) |
| WO (1) | WO2018175688A1 (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3600221A4 (en) * | 2017-03-22 | 2021-01-13 | Bonti, Inc. | BOTULINUM NEUROTOXINS FOR USE IN THERAPY |
| EP4137149A1 (en) * | 2017-04-21 | 2023-02-22 | Bonti, Inc. | Initiating neurotoxin treatments |
| US20190183987A1 (en) * | 2017-12-18 | 2019-06-20 | Bonti, Inc. | Neurotoxins for use in minimizing scarring |
| GB201815844D0 (en) * | 2018-09-28 | 2018-11-14 | Ipsen Biopharm Ltd | Therapeutic & comestic uses of botulinum neurotoxin serotype e |
| US11957740B2 (en) | 2021-03-13 | 2024-04-16 | Prime Bio, Inc. | Complex of botulinum neurotoxin E and its binding protein as a formulation with enhanced potency |
| GB202206362D0 (en) * | 2022-04-29 | 2022-06-15 | Ipsen Biopharm Ltd | Treatment of upper facial lines |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2123837C1 (ru) * | 1998-05-27 | 1998-12-27 | Бритун Юлия Анатольевна | Способ устранения морщин |
| DE19925739A1 (de) | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
| US7691983B2 (en) * | 2000-07-21 | 2010-04-06 | Allergan, Inc. | Chimera botulinum toxin type E |
| GB0111146D0 (en) | 2001-05-04 | 2001-06-27 | Imp College Innovations Ltd | Methods |
| US20040009180A1 (en) * | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
| US8734810B2 (en) | 2003-10-29 | 2014-05-27 | Allergan, Inc. | Botulinum toxin treatments of neurological and neuropsychiatric disorders |
| US7429386B2 (en) * | 2004-09-03 | 2008-09-30 | Allergan, Inc. | Stretch mark treatment |
| US20060067950A1 (en) | 2004-09-27 | 2006-03-30 | Merz Pharma Gmbh & Co. Kgaa | Clostridial neurotoxins for use in wound healing |
| US20060073208A1 (en) * | 2004-10-01 | 2006-04-06 | Allergan, Inc. | Cosmetic neurotoxin compositions and methods |
| US20090324647A1 (en) | 2005-10-11 | 2009-12-31 | Borodic Gary E | Albumin-Free Botulinum Toxin Based Pharmaceutical Compositions Containing a Hyaluronidase and Methods of Use |
| US8361055B2 (en) * | 2008-11-25 | 2013-01-29 | Tucker Peter L | Syringe and method for reconstitution of dry-form drugs and medicines |
| PL2379104T3 (pl) * | 2008-12-31 | 2018-07-31 | Revance Therapeutics, Inc. | Preparaty toksyny botulinowej do wstrzykiwania |
| US8129139B2 (en) * | 2009-07-13 | 2012-03-06 | Allergan, Inc. | Process for obtaining botulinum neurotoxin |
| EP2467477B1 (en) * | 2009-08-17 | 2014-05-07 | East Carolina University | Fast acting snare-cleaving enzymes |
| JP2011157331A (ja) * | 2010-02-03 | 2011-08-18 | Chemo-Sero-Therapeutic Research Inst | 高用量投与が可能なボツリヌス毒素製剤 |
| US20120258132A1 (en) | 2011-03-29 | 2012-10-11 | Allergan, Inc. | Vagal Nerve-Based Disorders |
| AU2012276512B2 (en) * | 2011-06-27 | 2016-04-21 | Sang Duck Kim | Pharmaceutical composition for treating scars on the skin, and method for treating scars on the skin using same |
| BR112014011137A2 (pt) * | 2011-11-09 | 2018-06-12 | Merz Pharma Gmbh & Co Kgaa | polinucleotídeo, vetor, célula hospedeira, polipeptídeo, anticorpo, método para a produção de um polipeptídeo, método para a produção de um medicamento |
| US10076558B2 (en) * | 2014-02-18 | 2018-09-18 | Rnw Skn, Llc | Prophylactic normalization of cutaneous wound repair |
| AU2015241144A1 (en) * | 2014-04-03 | 2016-11-10 | Gary D. Hack | Methods and compositions for enhancing and extending the cosmetic effects of non-surgical dermal interventions |
| US10647750B2 (en) * | 2015-01-09 | 2020-05-12 | Ipsen Bioinnovation Limited | Cationic neurotoxins |
| CN109069608A (zh) * | 2015-10-29 | 2018-12-21 | 雷文斯治疗公司 | 具有长的治疗或美容效应持续时间的可注射肉毒杆菌毒素制剂以及其使用方法 |
| AU2017277761B2 (en) * | 2016-06-10 | 2021-11-11 | Lonza Ltd | Method for stabilizing proteins |
| WO2018106339A1 (en) * | 2016-12-06 | 2018-06-14 | Bonti, Inc. | Botulinum neurotoxins for use in tendon repair surgery |
| EP3600221A4 (en) * | 2017-03-22 | 2021-01-13 | Bonti, Inc. | BOTULINUM NEUROTOXINS FOR USE IN THERAPY |
| CA3057304A1 (en) * | 2017-03-22 | 2018-09-27 | Bonti, Inc. | Botulinum neurotoxins for treating traumatic injuries |
| EP4137149A1 (en) * | 2017-04-21 | 2023-02-22 | Bonti, Inc. | Initiating neurotoxin treatments |
| EP3615669A4 (en) * | 2017-04-28 | 2021-05-12 | Bonti, Inc. | BOTULINIC NEUROTOXINS PRODUCTION PROCESSES |
| WO2018233813A1 (en) * | 2017-06-20 | 2018-12-27 | Merz Pharma Gmbh & Co. Kgaa | NOVEL RECOMBINANT BOTULINUM TOXINS WITH INCREASED DURATION |
| CA3068292A1 (en) * | 2017-06-26 | 2019-01-03 | Bonti, Inc. | Clostridial neurotoxin formulations and use |
| US20190183987A1 (en) * | 2017-12-18 | 2019-06-20 | Bonti, Inc. | Neurotoxins for use in minimizing scarring |
| JP2021520373A (ja) * | 2018-04-03 | 2021-08-19 | ボンチ インコーポレイテッド | Ｃｇｒｐを阻害する際に使用するための神経毒素 |
| US10464178B1 (en) * | 2018-10-11 | 2019-11-05 | Samuel J. Steeb | Method and assembly for docking and retrieving a filament holding device |
| KR20220054371A (ko) * | 2019-08-30 | 2022-05-02 | 이온 바이오파마, 인크. | 두통 치료에 사용하기 위한 신경독소 조성물 |
-
2018
- 2018-03-22 EP EP18772391.1A patent/EP3600221A4/en active Pending
- 2018-03-22 CA CA3057302A patent/CA3057302A1/en active Pending
- 2018-03-22 RU RU2019132648A patent/RU2766147C2/ru active
- 2018-03-22 WO PCT/US2018/023709 patent/WO2018175688A1/en unknown
- 2018-03-22 BR BR112019019743-5A patent/BR112019019743B1/pt active IP Right Grant
- 2018-03-22 US US16/496,011 patent/US11260114B2/en active Active
- 2018-03-22 RU RU2022102750A patent/RU2022102750A/ru unknown
- 2018-03-22 JP JP2020501424A patent/JP2020511548A/ja active Pending
- 2018-03-22 MX MX2019011196A patent/MX2019011196A/es unknown
- 2018-03-22 CN CN201880033758.1A patent/CN110691579A/zh active Pending
- 2018-03-22 KR KR1020197030538A patent/KR20190126894A/ko not_active Application Discontinuation
- 2018-03-22 AU AU2018237198A patent/AU2018237198B2/en active Active
-
2019
- 2019-09-20 MX MX2022010186A patent/MX2022010186A/es unknown
-
2022
- 2022-02-28 US US17/652,917 patent/US20230027850A1/en active Pending
- 2022-08-11 AU AU2022215253A patent/AU2022215253A1/en active Pending
-
2023
- 2023-03-07 JP JP2023034649A patent/JP2023076463A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020511548A5 (ja) | ||
| Chandrashekar et al. | Alopecia areata—successful outcome with microneedling and triamcinolone acetonide | |
| Levy et al. | Complications of minimally invasive cosmetic procedures: prevention and management | |
| JP2016540785A5 (ja) | ||
| JP2019529043A5 (ja) | ||
| Hartmann et al. | Complications associated with cutaneous aesthetic procedures | |
| RU2019132648A (ru) | Применение ботулинических нейротоксинов в лечении | |
| Heppt et al. | Current strategies in the treatment of scars and keloids | |
| JP2005524663A5 (ja) | ||
| Glaser et al. | Periorbital rejuvenation: overview of nonsurgical treatment options | |
| Alster et al. | Microneedling treatment of striae distensae in light and dark skin with long-term follow-up | |
| Scuderi et al. | A survey of patient satisfaction with use of microwave device for axillary hyperhidrosis | |
| Mobley et al. | Soft tissue trauma and scar revision | |
| Kontis | The art of camouflage: when can a revision rhinoplasty be nonsurgical? | |
| Chung et al. | Current protocol for aesthetic scar management in thyroid surgery | |
| Shokri et al. | Paradigms in complex facial scar management | |
| KR101357999B1 (ko) | 보툴리눔 에이형 독소의 액상제품 | |
| Vent et al. | Prevention and treatment of complications after polymethylmethacrylate-microspheres injections | |
| RU2020121973A (ru) | Нейротоксины для применения при уменьшении образования рубцов | |
| Dickey et al. | Noninvasive Facial Rejuvenation. Part 2: Physician-Directed—Neuromodulators and Fillers | |
| Lauchli et al. | Treatment of hyperhidrosis with botulinum toxin A | |
| Bennett et al. | Introduction to cosmetic dermatology | |
| Kocman et al. | Freestyle perforator-based fasciocutaneous flap reconstruction in Nicolau syndrome-related tissue necrosis | |
| US8454975B1 (en) | Method for enhancing skin appearance | |
| Sameera et al. | BOTOX-A COMPREHENSIVE REVIEW AND ITS USES IN DENTISTRY |